ABT vs CPHI · P/E 25, rev $44.33B vs rev $4.1M
Abbott Laboratories (ABT) versus China Pharma Holdings Inc (CPHI) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
China Pharma Holdings Inc (CPHI) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported CPHI revenue for 2025-12-31 was $4.1M. Net income was -$3.2M. Revenue was down 8.5% from 2024-12-31 to 2025-12-31. CPHI currently screens at market cap $29.0M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. CPHI currently screens at market cap $29.0M.
Not investment advice. Open the ABT and CPHI stock pages for the full models.
Not investment advice.